– Findings from the Phase 1b portion of company’s Phase 1b/2 study in second-line KRAS-mutated mCRC highlight the safety and promising efficacy of onvansertib in combination with standard-of-care – – These peer-reviewed published data are part of the Phase 1b/2 data Cardiff Oncology…